| Статус: | Active, not recruiting |
| Фаза: | Phase 3 |
| Начало: | 2 августа 2022 г. |
| Окончание: | 1 июля 2025 г. |
| Описание: | The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with unresectable or metastatic melanoma. |
| смотреть на ClinicalTrials.gov |